AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.

Presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, data also include week-28 findings from a phototherapy substudy, in which treatment groups receiving RINVOQ plus whole-body narrowband ultraviolet B (NB-UVB) phototherapy showed numerically higher repigmentation responses than groups receiving RINVOQ alone.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.